Cap

Zacks Small Cap Research – OMH: Backdrop of Industry Fundamentals, Positive Implications – Go Health Pro

by
Zacks Small Cap Research – OMH: Backdrop of Industry Fundamentals, Positive Implications – Go Health Pro

By M. Marin NASDAQ:OMH READ THE FULL OMH RESEARCH REPORT HDB sales volume up in 2024 … Ohmyhome Ltd (NASDAQ:OMH), a Singapore-based technology company that operates an online real estate platform, has experienced substantial momentum, reflecting the ongoing strength of the domestic property market and its growth initiatives. For example, resale prices and volume sales … Read more

Zacks Small Cap Research – MGRM: Monogram’s Potential for 2025 Commercialization of its mBôs Total Knee Arthroplasty Robotic System Supports Price Target of $6.00. – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT Regulatory Update On February 26, 2025, Monogram (NASDAQ:MGRM) announced an update regarding its 510(k) premarket filing submission to the FDA for the company’s mBôs TKA System. The company stated it had completed all supplemental testing and submitted its formal response to the Additional Information … Read more

Zacks Small Cap Research – SNGX: Presentation Highlights HyBryte Potential in CTCL… – Go Health Pro

by
Zacks Small Cap Research – SNGX: Presentation Highlights HyBryte Potential in CTCL… – Go Health Pro

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Presentation Highlights HyBryte Potential in CTCL In January 2025, Dr. Neal Bhatia presented at two dermatology conferences on “Off-Label Uses of PDT” (photodynamic therapy). Dr. Bhatia is the Director of Clinical Dermatology at Therapeutics Clinical Research, a member of Soligenix’s (NASDAQ:SNGX) scientific … Read more

Zacks Small Cap Research – GRCE: STRIVE-ON Results Reported – Go Health Pro

by

By John Vandermosten, CFA NASDAQ:GRCE READ THE FULL GRCE RESEARCH REPORT Grace Therapeutics, Inc (NASDAQ:GRCE) reported fiscal year (FY) third quarter results following a series of announcements regarding conference participation, the raise of additional capital and results from the Phase III STRIVE-ON trial for GTx-104. The most important information was the data from the Phase … Read more

Zacks Small Cap Research – TELO Announces Breakthrough – Go Health Pro

by

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. … Read more

x